The Japanese drugmaker said IntraBio’s expertise would strengthen capabilities across its rare disease pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results